Item 1(a). | Name of Issuer: |
Rhythm Pharmaceuticals, Inc. (the Issuer)
Item 1(b). | Address of Issuers Principal Executive Offices: |
222 Berkely Street, 12th Floor
Boston, MA 02116
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the Reporting Persons) are:
Perceptive Advisors LLC (Perceptive Advisors)
Joseph Edelman (Mr. Edelman)
Perceptive Life Sciences Master Fund, Ltd. (the Master Fund)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
NewYork, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common stock, $0.001 par value per share (Common Stock)
76243J105
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to thisSchedule 13G. The ownership percentages reported are based on an aggregate of 59,096,454 shares of Common Stock outstanding as of November 1, 2023, as reported by the Issuer in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.